The Viveve PURSUIT Trial is a pivotal U.S. Stress Urinary Incontinence trial that has completed all subject 12-month follow-up visits
Topline results of primary efficacy endpoint planned in January 2023.
Viveve Reports Third Quarter 2022 Financial ResultsRead The Report
Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary IncontinenceRead The Announcement
Pivotal U.S. Investigational Device Exemption (IDE) cleared trial
PURSUIT is a randomized, double-blinded, sham-controlled, IDE-cleared trial that enrolled 415 subjects with moderate SUI at approximately 30 study sites in the United States. Subjects were randomized in a 2:1 ratio to the active Viveve treatment or an inert sham treatment.
Viveve aspires to be the leader
in the treatment of female
Stress Urinary Incontinence
The internationally patented Viveve® System incorporates Cryogen-cooled Monopolar Radiofrequency (CMRF) technology to uniformly provide an endovaginal treatment that is non-ablative.
The Viveve Leadership Team
The Viveve leadership team is an experienced group of individuals dedicated to upholding our values and achieving our vision and mission.Meet the Senior Leadership Team
Viveve Career Opportunities
The Viveve team is dedicated to working together to find innovative, non-invasive products for female Stress Urinary Incontinence. Learn about our culture.Explore Career Opportunities